cosmetic/obesity

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to the use of a dihydrochalcone-rich phenolic fraction in the cosmetic treatment of mammals in order to limit the weight, to improve the aesthetic appearance of the body and to treat certain non-pathological forms of

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to the use of a dihydrochalcone-rich phenolic fraction in the cosmetic treatment of mammals in order to limit the weight, to improve the aesthetic appearance of the body and to treat certain non-pathological forms of

The invention concerns Allium sativum (garlic) bulb extracts and uses thereof. Said compositions can be advantageously and more particularly used in the pharmaceutical and cosmetics industry. The invention thus also concerns therapeutic compositions (medicaments), particularly for the treatment of

This application is a 371 of PCT/ES02/00231, filed on May 16, 2002, which claims benefit of priority to ES 200101200, filed on May 16, 2001. The invention refers to the use of oral compositions for the treatment of non-diabetic mammals, including humans suffering from obesity and/or overweight. The

TECHNICAL FIELD The present invention relates to an obesity preventing or therapeutic agent including an extract of lysimachiae foenum-graeci herba as an active ingredient, and more particularly to a raw material, a functional food, cosmetic, and a crude drug for preventing/treating obesity, which

CROSS-REFERENCE TO RELATED APPLICATIONS Also, each of the following copending applications are assigned to the assignee hereof. Application Ser. No. 08/429,492, now U.S. Pat. No. 5,705,167 and Ser. No. 08/429,045, now U.S. Pat. No. 5,574,036, and applications Ser. No. 08/356,913, now U.S. Pat. No.

The invention relates to an antiadipose topical treatment composition and to the uses of this composition and/or of garlic bulbs extracts cosmetically for preventively or curatively treating cellulite and localized dermal excess adipose, or therapeutically for treating obesity. More than 90% of

TECHNICAL FIELD The present disclosure relates to a natural composition showing an outstanding effect in a variety of applications, and more particularly, to a natural plant composite extract showing an outstanding effect in relieving menopausal symptoms. The present application claims priority to

FIELD OF THE INVENTION This invention relates to the field of cell culture and more specifically to the culture and use of stem cells. BACKGROUND Brown fat is one of two types of adipose tissue found in the human body. During embryogenesis, brown fat is derived from the differentiation of the

BACKGROUND Brown fat is one of two types of adipose tissue found in the human body. During embryogenesis, brown fat is derived from the differentiation of the mesoderm. Brown fat is involved in development and homeostasis by providing metabolic tissue capable of providing heat. Brown fat helps

TECHNICAL FIELD Thee present invention relates to a carbon dioxide-containing viscous composition which is capable of treating or ameliorating itching accompanying mucocutaneous diseases or mucocutaneous disorders such as athlete's foot, insect bite, atopic dermatitis, nummular eczema, xeroderma,

The invention concerns compositions comprising substituted 1,3-diphenylprop-2-en-1-one derivatives and uses thereof, particularly in the fields of human and veterinary health. The compounds according to the invention have pharmacological antioxidant properties and PPAR.alpha. and PPAR.gamma.

This application is the US national phase of international application PCT/FR2003/002128 filed 8 Jul. 2003 which designated the U.S. and claims benefit of FR 02/08570, dated 8 Jul. 2002, the entire content of which is hereby incorporated by reference. The invention concerns compositions comprising

The invention concerns compositions comprising substituted 1,3-diphenylprop-2-en-1-one derivatives and uses thereof, particularly in the fields of human and veterinary health. The compounds according to the invention have pharmacological antioxidant properties and PPAR.alpha. and PPAR.gamma.

This application is the U.S. national phase of international application PCT/FR02/02831, filed in French on 08 Aug. 2002, which designated the U.S. PCT/FR02/02831 claims priority to FR Application No. 01 10645, filed 09 Aug. 2001. The entire contents of these applications are incorporated herein by